Global Life Expectancy, Disease Burden Set to Keep Improving
By Elana Gotkine HealthDay Reporter
WEDNESDAY, May 22, 2024 -- Life expectancy and age-standardized disease burden are expected to continue improving between 2022 and 2050, according to the Global Burden of Disease (GBD) study, published in the May 18 issue of The Lancet.
Stein Emil Vollset, M.D., M.P.H., and colleagues from the GBD 2021 Forecasting Collaborators provide a reference forecast and alternative scenarios assessing disease burden trajectories if selected sets of risk factors were eliminated from current levels by 2050.
The researchers found that global and super-regional life expectancy will increase from 2022 to 2050 in the reference scenario forecast, but improvement will be at a slower pace than in the three decades preceding the COVID-19 pandemic. Compared with super-regions with higher life expectancies, super-regions with comparatively low life expectancies were forecast to have the greatest gains in future life expectancy, leading to a trend toward convergence in life expectancy across locations. Forecasted healthy life expectancy patterns were similar to those of life expectancies at the super-region level. For the reference scenario, health will improve in the coming decades, with all-cause age-standardized disability-adjusted life-year (DALY) rates decreasing in every GBD super-region. However, increases in the total DALY burden measured in counts will increase in every super-region. It is forecast that DALY counts and age-standardized DALY rates will continue to shift from communicable, maternal, neonatal, and nutritional diseases to noncommunicable diseases.
"Our reference forecasts of disease burden and life expectancy to 2050 indicate a continued, albeit slower, improvement in the health status of the world," the authors write.
Several authors disclosed ties to industry.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Higher COVID-19 Vaccination Rates Tied to Decrease in Childhood Asthma Symptoms
WEDNESDAY, July 3, 2024 -- Higher COVID-19 vaccination rates are associated with a lower prevalence of parent-reported childhood asthma symptoms, according to a research letter...
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.